HOME > LATEST

LATEST

BUSINESS Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan

November 18, 2025
BUSINESS Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan

November 18, 2025
BUSINESS Nipro Files for Full Approval of Stemirac Cell Therapy

November 18, 2025
BUSINESS Dupixent 200 mg Pen Now Available in Japan: Sanofi

November 18, 2025
BUSINESS Maruho Licenses Antibiotic Faropenem to China’s CR Gosun

November 18, 2025
BUSINESS Otsuka/Ionis’ HAE Prevention Drug Wins CHMP Backing

November 18, 2025
BUSINESS Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes

November 18, 2025
REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds

November 17, 2025
COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform

November 17, 2025
REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution

November 17, 2025
BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar

November 17, 2025
REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid

November 17, 2025
BUSINESS Kura, Kyowa Kirin Land US FDA Approval for AML Med Komzifti

November 17, 2025
REGULATORY Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines

November 13, 2025
REGULATORY Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products

November 13, 2025
REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year

October 30, 2025
REGULATORY MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications

October 14, 2025
BUSINESS Chugai to Develop Roche’s GLP-1/GIP Agent CT-388 in Japan

October 14, 2025
BUSINESS JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan

October 14, 2025
REGULATORY Japan’s Healthcare Spending Reaches 48.1 Trillion Yen in FY2023

October 14, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…